Table.
Top canonical pathways identified by Ingenuity pathway analysis
| Top canonical pathways | P | Ratio | Genes |
|---|---|---|---|
| Day 5 | |||
| Amyloid processing | 9.21E-04 | 2/61 (0.033) | PRKACB, CSNK2A1 |
| Putrescine biosynthesis III | 1.77E-03 | 1/4 (0.25) | ODC1 |
| IGF-1 signaling | 3.28E-03 | 2/107 (0.019) | PRKACB, CSNK2A1 |
| NF-κB signaling | 1.01E-02 | 2/181 (0.011) | PRKACB, CSNK2A1 |
| RAR activation | 1.05E-02 | 2/195 (0.01) | PRKACB, CSNK2A1 |
| Day 9 | |||
| Actin cytoskeleton signaling | 1.02E-12 | 32/242 (0.132) | RAF1, MPRIP, PDGFA, ARPC5, EGF, SSH1, SLC9A1, PDGFC, ROCK2, PTK2, SHC1, DIAPH1, FGF18, MAP2K2, FLNA, EZR, MAP2K1, ARHGEF12, GRB2, CSK, CRKL, GNA12, ITGA2, RAC1, GSN, ROCK1, PIP5K1C, CYFIP1, MYH9, WASF2, ACTN4, PIP4K2A |
| Integrin signaling | 9.2E-11 | 28/208 (0.135) | RAF1, FYN, RAP2A, MPRIP, ARPC5, ILK, ITGB3, PTK2, NCK2, SHC1, AKT1, MAP2K2, MAP2K1, VASP, SRC, GRB2, ASAP1, CRKL, RALB, ITGA2, RAC1, TNK2, ROCK1, ARF1, ARF3, LIMS1, ACTN4, FNBP1 |
| Ephrin receptor signaling | 1.6E-10 | 26/210 (0.124) | RAF1, FYN, AXIN1, PDGFA, ARPC5, GNB5, EGF, PDGFC, GNB1, ROCK2, PTK2, NCK2, SHC1, AKT1, MAP2K2, ATF4, MAP2K1, SRC, GRB2, CRKL, GNA12, ITGA2, RAC1, GNAZ, ROCK1, ACP1 |
| Molecular mechanisms of cancer | 1.15E-09 | 36/388 (0.093) | RAF1, FYN, RAP2A, AXIN1, CTNNA1, PTK2, TGFBR2, CASP6, SHC1, AKT1, MAP2K2, ARHGEF3, MAP2K1, RALGDS, PRKCA, SRC, ARHGEF12, PRKCQ, CASP3, GRB2, GNA12, ADCY3, RALB, RAC1, GNAZ, RALBP1, FADD, BCL2L1, CBL, FOXO1, IRS1, CDKN1A, ARHGEF18, MAP2K3, DIABLO, FNBP1 |
| VEGF signaling | 1.18E-09 | 18/109 (0.165) | EIF1AY, SRC, RAF1, PTPN6, GRB2, PDGFC, ROCK2, PTK2, ROCK1, SHC1, BCL2L1, AKT1, FOXO1, MAP2K2, FOXO3, ACTN4, MAP2K1, PRKCA |